Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. (NASDAQ: ISPC) operates a global technology platform connecting life science researchers with healthcare providers to streamline biospecimen procurement. This page aggregates official company announcements, financial disclosures, and operational updates critical for understanding its role in advancing medical research.
Investors and stakeholders gain real-time access to press releases covering strategic partnerships, regulatory milestones, and marketplace expansions. Key updates include earnings reports, technology innovations like the Next Day Quote program, and collaborations enhancing global specimen availability.
Bookmark this page for timely insights into iSpecimen’s progress in addressing biospecimen sourcing challenges. Regular updates ensure you stay informed about developments impacting oncology research, infectious disease studies, and the company’s growing healthcare network.
iSpecimen Inc. (ISPC) reported strong Q2 2024 results, with revenue increasing 76% year-over-year to $2.86 million. The company's operational improvements, including the Next Day Quotes program and Supplier Refresh initiative, contributed to this growth. Key highlights include:
- 58% conversion rate of Next Day Quotes to purchase orders in H1 2024
- Over 105 unique supplier organizations under contract as of June 30, 2024
- Cash and available-for-sale securities of $2.15 million as of June 30, 2024
The company's net loss decreased to $2.11 million, or $(0.19) per share, compared to a net loss of $3.50 million, or $(0.39) per share, in Q2 2023. iSpecimen also appointed Brielan Smiechowski as SVP of Sales and Business Development to focus on key customer accounts and implement a more robust outbound sales structure.
iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace connecting scientists with biospecimen providers for medical research, has announced its plans to report second quarter 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call and audio webcast at 8:30 a.m. Eastern Time, featuring remarks by CEO Tracy Curley.
Interested parties can join the live call at +1-800-717-1738 (U.S. Toll Free) or +1-646-307-1865 (International). A webcast will be available, and a replay of the call will be accessible until August 20, 2024. The earnings report and subsequent call may provide insights into iSpecimen's financial performance and future outlook.
iSpecimen Inc. (Nasdaq: ISPC) reported Q1 2024 financial results, highlighting a focus on Next Day Quotes program to expedite biospecimen transactions, resulting in improved market position and growth prospects. By strategically refining the supplier network, 40% of all quotes were Next Day Quotes in Q1 2024, with a high conversion rate to purchase orders. The Company aims to transition a majority of its business to Next Day Quotes for enhanced financial performance. Despite a reduction in revenue due to a decrease in specimen count, the average selling price per specimen increased, offsetting the impact. iSpecimen also announced a strategic partnership with TriMetis Life Sciences to enhance tissue-based research.
FAQ
What is the current stock price of Ispecimen (ISPC)?
What is the market cap of Ispecimen (ISPC)?
